About: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
Creator	Lin, Peng Wang, Ke Zhang, Zheng Wang, Bin Zhang, Zhe Chen, Zhi-Nan Wei, Ding Du, Hong Bian, Bian, Huijie Chen, -Nan Chen, Xiao-Chun Cui, Hong-Yong Dong, Ke Gang, Nan Gao, Zhao-Wei Geng, Jie-Jie Hao, Chun-Qiu Kang, Wen Kang, Wen-Zhen Lian, Jian-Qi Liu, Lin-Na Liu, Shuang-Shuang Miao, Jin-Lin Sun, Xiu-Xuan Tang, Hao Wang, Qing-Yi Xia, Jie-Lai Xie, Rong-Hua Yang, Xiang-Min Yao, Na Zhang, Kui Zheng, Zhu,
Source	MedRxiv
abstract	Background: SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion. Antibody against CD147 could block the infection of SARS-CoV-2. We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. Methods: All patients received recommended strategy from Diagnosis and Treatment for 2019 Novel Coronavirus Diseases released by National Health Commission of China. Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5. Patients hospitalized in the same period were observed as concurrent control. The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test. This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245. Findings:17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia. Funding:National Science and Technology Major Project.
has issue date	2020-03-24(xsd:dateTime)
bibo:doi	10.1101/2020.03.21.20040691
has license	medrxiv
sha1sum (hex)	f2e97a31530d31faf36ef78dcaf0a7fbe129e2f2
schema:url	https://doi.org/10.1101/2020.03.21.20040691
resource representing a document's title	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
resource representing a document's body	covid:f2e97a31530d31faf36ef78dcaf0a7fbe129e2f2#body_text
is schema:about of	named entity 'carry' named entity 'Interpretation' named entity 'SARS-CoV-2' named entity 'FAVORABLE' named entity 'SUPPORT' named entity 'MEPLAZUMAB' named entity 'SARS-COV-2' named entity 'patients' named entity 'pneumonia' named entity 'COVID-19' named entity 'CD147' named entity 'intravenous infusion' named entity 'infection' named entity 'therapeutic effects' named entity 'D-Dimer' named entity 'control group' named entity 'Lymphopenia' named entity 'CD147' named entity 'vomit' named entity 'preprint' named entity 'pneumonia' named entity 'inflammation' named entity 'up-regulated' named entity 'preprint' named entity 'peer review' named entity 'total bilirubin' named entity 'COVID' named entity 'pneumonia' named entity 'coronavirus' named entity '5.0' named entity 'follow-up' named entity 'lymphopenia' named entity 'pneumonia' named entity 'human tissues' named entity '2019 Novel Coronavirus' named entity 'spike protein' named entity 'serum' named entity 'peer review' named entity 'inflammation' named entity 'MERS-CoV' named entity 'COVID' named entity 'virus infection' named entity 'CRP' named entity 'radiographic' named entity 'preprint' named entity 'acute inflammation' named entity 'medRxiv' named entity 'control group' named entity 'PD-1' named entity 'cell adhesion' named entity 'mechanical ventilation' named entity 'Vero E6 cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software